Unicycive Therapeutics
We are a biotechnology company dedicated to developing treatments for certain medical conditions. Two of our programs are focused on kidney disease: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for treatment of acute kidney injury (AKI). Renazorb and UNI 494 were initially developed by, and licensed to us […]
June 10, 2021 Read More